| Theme | NASH 2018 | |
|---|---|---|
| Title | Diabetes Mellitus and NAFLD/NASH | |
| Publish Date | 2018/01 | |
| Author | Koutarou Soeda | Diabetes Research Center, Research Institute National Center for Global Health and Medicine |
| Author | Kohjiro Ueki | Diabetes Research Center, Research Institute National Center for Global Health and Medicine |
| [ Summary ] | Although fatty liver was historically thought to be a benign hepatic condition, lately, it has been considered as a potential pathophysiological state which can even lead to the development of malignancy in the background of liver fibrosis (nonalcoholic steatohepatitis ; NASH). NASH itself can be led by simple steatosis (nonalcoholic liver disease ; NAFLD) if it is accompanied by inflammation. Therefore, NAFLD/NASH is thought to be an important liver disease that increases the risk for liver cancer. Obesity and insulin resistance are the most fundamental risk factors of NAFLD/NASH, and chronic inflammation, oxidative stress, and ER (endoplasmic reticulum) stress are also well‒known exacerbation factors. On the other hand, the primary pathophysiology of type 2 diabetes mellitus is also visceral obesity and insulin resistance. Therefore, both type 2 diabetes mellitus and NAFLD/NASH are considered to be closely related to the metabolic syndrome. In this article, we will introduce epidemic and biological evidence or the close relationship between NAFLD/NASH and type 2 diabetes mellitus and an appropriate therapeutic strategy, improving the understanding on the underlying pathophysiology. |
|